全文获取类型
收费全文 | 3667284篇 |
免费 | 300158篇 |
国内免费 | 14561篇 |
专业分类
耳鼻咽喉 | 49228篇 |
儿科学 | 116193篇 |
妇产科学 | 95038篇 |
基础医学 | 577365篇 |
口腔科学 | 96519篇 |
临床医学 | 331279篇 |
内科学 | 656133篇 |
皮肤病学 | 95208篇 |
神经病学 | 317055篇 |
特种医学 | 143259篇 |
外国民族医学 | 503篇 |
外科学 | 560946篇 |
综合类 | 109345篇 |
现状与发展 | 25篇 |
一般理论 | 2460篇 |
预防医学 | 307063篇 |
眼科学 | 84093篇 |
药学 | 251254篇 |
22篇 | |
中国医学 | 10715篇 |
肿瘤学 | 178300篇 |
出版年
2021年 | 56550篇 |
2020年 | 35975篇 |
2019年 | 59357篇 |
2018年 | 73571篇 |
2017年 | 56225篇 |
2016年 | 62295篇 |
2015年 | 75840篇 |
2014年 | 110601篇 |
2013年 | 176452篇 |
2012年 | 111033篇 |
2011年 | 112961篇 |
2010年 | 122087篇 |
2009年 | 125654篇 |
2008年 | 98470篇 |
2007年 | 103264篇 |
2006年 | 112997篇 |
2005年 | 108191篇 |
2004年 | 108902篇 |
2003年 | 98545篇 |
2002年 | 87682篇 |
2001年 | 118781篇 |
2000年 | 112091篇 |
1999年 | 108060篇 |
1998年 | 67325篇 |
1997年 | 64746篇 |
1996年 | 62449篇 |
1995年 | 57866篇 |
1994年 | 51816篇 |
1993年 | 48338篇 |
1992年 | 74446篇 |
1991年 | 70101篇 |
1990年 | 65786篇 |
1989年 | 64594篇 |
1988年 | 59523篇 |
1987年 | 58245篇 |
1986年 | 54774篇 |
1985年 | 54598篇 |
1984年 | 49664篇 |
1983年 | 45223篇 |
1982年 | 42335篇 |
1981年 | 39699篇 |
1980年 | 37363篇 |
1979年 | 40327篇 |
1978年 | 35670篇 |
1977年 | 32364篇 |
1976年 | 29709篇 |
1975年 | 28009篇 |
1974年 | 29079篇 |
1973年 | 28102篇 |
1972年 | 26281篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
41.
Major depressive disorder and other neuropsychiatric disorders are often managed with long-term use of antidepressant medication. Fluoxetine, an SSRI antidepressant, is widely used as a first-line treatment for neuropsychiatric disorders. However, fluoxetine has also been shown to increase the risk of metabolic diseases such as non-alcoholic fatty liver disease. Fluoxetine has been shown to increase hepatic lipid accumulation in vivo and in vitro. In addition, fluoxetine has been shown to alter the production of prostaglandins which have also been implicated in the development of non-alcoholic fatty liver disease. The goal of this study was to assess the effect of fluoxetine exposure on the prostaglandin biosynthetic pathway and lipid accumulation in a hepatic cell line (H4-II-E-C3 cells). Fluoxetine treatment increased mRNA expression of prostaglandin biosynthetic enzymes (Ptgs1, Ptgs2, and Ptgds), PPAR gamma (Pparg), and PPAR gamma downstream targets involved in fatty acid uptake (Cd36, Fatp2, and Fatp5) as well as production of 15-deoxy-Δ12,14PGJ2 a PPAR gamma ligand. The effects of fluoxetine to induce lipid accumulation were attenuated with a PTGS1 specific inhibitor (SC-560), whereas inhibition of PTGS2 had no effect. Moreover, SC-560 attenuated 15-deoxy-Δ12,14PGJ2 production and expression of PPAR gamma downstream target genes. Taken together these results suggest that fluoxetine-induced lipid abnormalities appear to be mediated via PTGS1 and its downstream product 15d-PGJ2 and suggest a novel therapeutic target to prevent some of the adverse effects of fluoxetine treatment. 相似文献
42.
Deitelzweig Steve Luo Xuemei Nguyen Jennifer L. Malhotra Deepa Emir Birol Russ Cristina Li Xiaoyan Lee Theodore C. Ferri Mauricio Wiederkehr Danny Reimbaeva Maya Barnes Geoffrey D. Piazza Gregory 《Journal of thrombosis and thrombolysis》2022,54(4):696-696
Journal of Thrombosis and Thrombolysis - 相似文献
43.
Boffa Joseph W. Tock Jamie L. Morabito Danielle M. Schmidt Norman B. 《Cognitive therapy and research》2022,46(5):1016-1029
Cognitive Therapy and Research - Despite interest in psychological inflexibility as a marker of suicide risk, no measure of psychological inflexibility specific to SI exists. The present study... 相似文献
44.
45.
46.
47.
Triposkiadis Filippos Xanthopoulos Andrew Skoularigis John Starling Randall C. 《Heart failure reviews》2022,27(6):1991-2003
Heart Failure Reviews - The nitric oxide (NO)–guanylate cyclase (GC)–cyclic guanosine monophosphate (cGMP) pathway plays an important role in cardiovascular, pulmonary and renal... 相似文献
48.
Comprehensive evidence regarding the treatment of non-anaemic iron deficiency in patients undergoing valvular heart surgery is lacking. This study aimed to investigate the association between non-anaemic iron deficiency and postoperative outcomes in these patients. We retrospectively analysed 321 patients of which 180 (56%) had iron deficiency (defined as serum ferritin < 100 ng.ml-1 or < 300 ng.ml-1 with transferrin saturation < 20%). While the iron-deficient group had lower pre-operative haemoglobin levels than the non-iron deficient group (median (IQR [range]) 134 (127–141 [120–172]) g.l-1, 143 (133–150 [120–179]) g.l-1, p = 0.001), there was no between-group difference in allogeneic red blood cell transfusion. Median (IQR [range]) days alive and out of hospital at postoperative day 90 was 1 day shorter in the iron-deficient group (80 (77–82 [9–85]) days vs. 81 (79–83 [0–85]) days, p = 0.026). In multivariable analysis, only cardiopulmonary bypass duration (p = 0.032) and intra-operative allogeneic red blood cell transfusion (p = 0.011) were significantly associated with reduced days alive and out of hospital at postoperative day 90. Iron deficiency did not exert any adverse influence on secondary outcomes except length of hospital stay. Our findings indicate that non-anaemic iron deficiency alone is not associated with adverse effects in patients undergoing valvular heart surgery when it does not translate into an increased risk of allogeneic transfusion. 相似文献
49.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
50.
Vilar-Compte Mireya Gaitán-Rossi Pablo Félix-Beltrán Lucía Bustamante Arturo V. 《Journal of immigrant and minority health / Center for Minority Public Health》2022,24(1):65-77
Journal of Immigrant and Minority Health - COVID-19 has disproportionally affected underrepresented minorities (URM) and low-income immigrants in the United States. The aim of the study is to... 相似文献